Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Scott David Solomon, M.D.

TitleProfessor of Medicine
InstitutionBrigham and Women's Hospital
DepartmentMedicine
AddressBrigham and Women's Hospital
Cardiovascular
75 Francis St
Boston MA 02115
Phone857/307-1960
Fax857/307-1944

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Kutyifa V, Pouleur AC, Knappe D, Al-Ahmad A, Gibinski M, Wang PJ, McNitt S, Merkely B, Goldenberg I, Solomon SD, Moss AJ, Zareba W. Dyssynchrony and the risk of ventricular arrhythmias. JACC Cardiovasc Imaging. 2013 Apr; 6(4):432-44.
    View in: PubMed
  2. Gheorghiade M, Böhm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A, Maggioni AP. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA. 2013 Mar 20; 309(11):1125-35.
    View in: PubMed
  3. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O'Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013 Mar 28; 368(13):1210-9.
    View in: PubMed
  4. Kutyifa V, Kloppe A, Zareba W, Solomon SD, McNitt S, Polonsky S, Barsheshet A, Merkely B, Lemke B, Nagy VK, Moss AJ, Goldenberg I. The Influence of Left Ventricular Ejection Fraction on the Effectiveness of Cardiac Resynchronization Therapy: MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy). J Am Coll Cardiol. 2013 Mar 5; 61(9):936-44.
    View in: PubMed
  5. Omland T, Pfeffer MA, Solomon SD, de Lemos JA, Røsjø H, Saltyte Benth J, Maggioni A, Domanski MJ, Rouleau JL, Sabatine MS, Braunwald E. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. J Am Coll Cardiol. 2013 Mar 26; 61(12):1240-9.
    View in: PubMed
  6. Knappe D, Pouleur AC, Shah AM, Bourgoun M, Brown MW, Foster E, Pfeffer MA, Moss AJ, Solomon SD. Acute Effects of Withdrawal of Cardiac Resynchronization Therapy on Left and Right Ventricular Function, Dyssynchrony, and Contractile Function in Patients With New York Heart Association Functional Class I/II Heart Failure: MADIT-CRT. J Card Fail. 2013 Mar; 19(3):149-55.
    View in: PubMed
  7. McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, Solomon SD, Tendera M, van Veldhuisen DJ, Albizem M, Cheng S, Scarlata D, Swedberg K, Young JB. Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF). Eur J Heart Fail. 2013 Mar; 15(3):334-41.
    View in: PubMed
  8. Shah SJ, Heitner JF, Sweitzer NK, Anand IS, Kim HY, Harty B, Boineau R, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Lewis EF, Markov V, O'Meara E, Kobulia B, Shaburishvili T, Solomon SD, Pitt B, Pfeffer MA, Li R. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail. 2013 Mar 1; 6(2):184-92.
    View in: PubMed
  9. Hsu JC, Solomon SD, McNitt S, Moss AJ, Foster E. Reply. J Am Coll Cardiol. 2012 Nov 20; 60(21):2258-9.
    View in: PubMed
  10. Kutyifa V, Solomon SD, Bourgoun M, Shah AM, Pouleur AC, Knappe D, McNitt S, Wang PJ, Merkely B, Pfeffer M, Moss AJ, Zareba W. Effects of cardiac resynchronization therapy on left ventricular mass and wall thickness in mild heart failure patients in MADIT-CRT. Heart Rhythm. 2013 Mar; 10(3):354-60.
    View in: PubMed
  11. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S, Bertrand M, Fuster V. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012 Dec 20; 367(25):2375-84.
    View in: PubMed
  12. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 Dec 6; 367(23):2204-13.
    View in: PubMed
  13. Shah AM, Bourgoun M, Narula J, Jacobson AF, Solomon SD. Influence of Ejection Fraction on the Prognostic Value of Sympathetic Innervation Imaging With Iodine-123 MIBG in Heart Failure. JACC Cardiovasc Imaging. 2012 Nov; 5(11):1139-46.
    View in: PubMed
  14. Tamez H, Zoccali C, Packham D, Wenger J, Bhan I, Appelbaum E, Pritchett Y, Chang Y, Agarwal R, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Singh B, Zehnder D, Pachika A, Manning WJ, Shah A, Solomon SD, Thadhani R. Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J. 2012 Dec; 164(6):902-909.e2.
    View in: PubMed
  15. Vardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B, Solomon SD. Influence of Baseline and Worsening Renal Function on Efficacy of Spironolactone in Patients With Severe Heart Failure: Insights From RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol. 2012 Nov 13; 60(20):2082-9.
    View in: PubMed
  16. Lam CS, Shah AM, Borlaug BA, Cheng S, Verma A, Izzo J, Oparil S, Aurigemma GP, Thomas JD, Pitt B, Zile MR, Solomon SD. Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency. Eur Heart J. 2013 Mar; 34(9):676-83.
    View in: PubMed
  17. Platz E, Lattanzi A, Agbo C, Takeuchi M, Resnic FS, Solomon SD, Desai AS. Utility of lung ultrasound in predicting pulmonary and cardiac pressures. Eur J Heart Fail. 2012 Nov; 14(11):1276-84.
    View in: PubMed
  18. Platz E, Solomon SD. Point-of-care echocardiography in the accountable care organization era. Circ Cardiovasc Imaging. 2012 Sep 1; 5(5):676-82.
    View in: PubMed
  19. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012 Oct 20; 380(9851):1387-95.
    View in: PubMed
  20. Zhao L, Tian L, Uno H, Solomon SD, Pfeffer MA, Schindler JS, Wei LJ. Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study. Clin Trials. 2012; 9(5):570-7.
    View in: PubMed
  21. Pedrizzetti G, Kraigher-Krainer E, De Luca A, Caracciolo G, Mangual JO, Shah A, Toncelli L, Domenichini F, Tonti G, Galanti G, Sengupta PP, Narula J, Solomon S. Functional strain-line pattern in the human left ventricle. Phys Rev Lett. 2012 Jul 27; 109(4):048103.
    View in: PubMed
  22. Shah AM, Solomon SD. Phenotypic and pathophysiological heterogeneity in heart failure with preserved ejection fraction. Eur Heart J. 2012 Jul; 33(14):1716-7.
    View in: PubMed
  23. Hsu JC, Solomon SD, Bourgoun M, McNitt S, Goldenberg I, Klein H, Moss AJ, Foster E. Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study. J Am Coll Cardiol. 2012 Jun 19; 59(25):2366-73.
    View in: PubMed
  24. Siminiak T, Wu JC, Haude M, Hoppe UC, Sadowski J, Lipiecki J, Fajadet J, Shah AM, Feldman T, Kaye DM, Goldberg SL, Levy WC, Solomon SD, Reuter DG. Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN Trial. Eur J Heart Fail. 2012 Aug; 14(8):931-8.
    View in: PubMed
  25. Castagno D, Skali H, Takeuchi M, Swedberg K, Yusuf S, Granger CB, Michelson EL, Pfeffer MA, McMurray JJ, Solomon SD. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. J Am Coll Cardiol. 2012 May 15; 59(20):1785-95.
    View in: PubMed
  26. Paskowitz DM, Nguyen QD, Gehlbach P, Handa JT, Solomon S, Stark W, Shaikh O, Semba C, Gadek TR, Do DV. Safety, tolerability, and bioavailability of topical SAR 1118, a novel antagonist of lymphocyte function-associated antigen-1: a phase 1b study. Eye (Lond). 2012 Jul; 26(7):944-9.
    View in: PubMed
  27. Vardeny O, Pouleur AC, Takeuchi M, Appelbaum E, Verma A, Prescott M, Smith B, Dahlof B, Solomon SD. Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass regression. J Renin Angiotensin Aldosterone Syst. 2012 Jun; 13(2):265-72.
    View in: PubMed
  28. Barkoudah E, Skali H, Uno H, Solomon SD, Pfeffer MA. Mortality rates in trials of subjects with type 2 diabetes. J Am Heart Assoc. 2012 Feb; 1(1):8-15.
    View in: PubMed
  29. Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012 Feb 15; 307(7):674-84.
    View in: PubMed
  30. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Nicolaides M, Richard A, Xiang Z, Armbrecht J, Pfeffer MA. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst. 2012 Sep; 13(3):387-93.
    View in: PubMed
  31. Meris A, Amigoni M, Verma A, Thune JJ, Køber L, Velazquez E, McMurray JJ, Pfeffer MA, Califf R, Levine RA, Solomon SD. Mechanisms and predictors of mitral regurgitation after high-risk myocardial infarction. J Am Soc Echocardiogr. 2012 May; 25(5):535-42.
    View in: PubMed
  32. Solomon SD. Vasodilators across the heart failure spectrum not all patients, and not all vasodilators, are created equal. J Am Coll Cardiol. 2012 Jan 31; 59(5):452-4.
    View in: PubMed
  33. Platz E, Hassanein AH, Shah A, Goldhaber SZ, Solomon SD. Regional right ventricular strain pattern in patients with acute pulmonary embolism. Echocardiography. 2012 Apr; 29(4):464-70.
    View in: PubMed
  34. Shah AM, Solomon SD. Myocardial deformation imaging: current status and future directions. Circulation. 2012 Jan 17; 125(2):e244-8.
    View in: PubMed
  35. Sabatine MS, Morrow DA, de Lemos JA, Omland T, Sloan S, Jarolim P, Solomon SD, Pfeffer MA, Braunwald E. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation. 2012 Jan 17; 125(2):233-40.
    View in: PubMed
  36. Skali H, Parving HH, Parfrey PS, Burdmann EA, Lewis EF, Ivanovich P, Keithi-Reddy SR, McGill JB, McMurray JJ, Singh AK, Solomon SD, Uno H, Pfeffer MA. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation. 2011 Dec 20; 124(25):2903-8.
    View in: PubMed
  37. Desai AS, Lewis EF, Li R, Solomon SD, Assmann SF, Boineau R, Clausell N, Diaz R, Fleg JL, Gordeev I, McKinlay S, O'Meara E, Shaburishvili T, Pitt B, Pfeffer MA. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J. 2011 Dec; 162(6):966-972.e10.
    View in: PubMed
  38. Brenyo A, Link MS, Barsheshet A, Moss AJ, Zareba W, Wang PJ, McNitt S, Huang D, Foster E, Estes M, Solomon SD, Goldenberg I. Cardiac resynchronization therapy reduces left atrial volume and the risk of atrial tachyarrhythmias in MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy). J Am Coll Cardiol. 2011 Oct 11; 58(16):1682-9.
    View in: PubMed
  39. Skali H, Solomon SD. Reducing infarct size with EPO in patients with ST-segment elevation myocardial infarction. Am J Kidney Dis. 2011 Dec; 58(6):876-8.
    View in: PubMed
  40. McMurray JJ, Uno H, Jarolim P, Desai AS, de Zeeuw D, Eckardt KU, Ivanovich P, Levey AS, Lewis EF, McGill JB, Parfrey P, Parving HH, Toto RM, Solomon SD, Pfeffer MA. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). Am Heart J. 2011 Oct; 162(4):748-755.e3.
    View in: PubMed
  41. Shah AM, Shin SH, Takeuchi M, Skali H, Desai AS, Køber L, Maggioni AP, Rouleau JL, Kelly RY, Hester A, Keefe D, McMurray JJ, Pfeffer MA, Solomon SD. Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren. Eur J Heart Fail. 2012 Feb; 14(2):185-92.
    View in: PubMed
  42. Shah AM, Hung CL, Shin SH, Skali H, Verma A, Ghali JK, Køber L, Velazquez EJ, Rouleau JL, McMurray JJ, Pfeffer MA, Solomon SD. Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. Am Heart J. 2011 Oct; 162(4):685-91.
    View in: PubMed
  43. Goldenberg I, Moss AJ, Hall WJ, Foster E, Goldberger JJ, Santucci P, Shinn T, Solomon S, Steinberg JS, Wilber D, Barsheshet A, McNitt S, Zareba W, Klein H. Predictors of response to cardiac resynchronization therapy in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). Circulation. 2011 Oct 4; 124(14):1527-36.
    View in: PubMed
  44. Shah AM, Lam CS, Cheng S, Verma A, Desai AS, Rocha RA, Hilkert R, Izzo J, Oparil S, Pitt B, Thomas JD, Zile MR, Aurigemma GP, Solomon SD. The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertension. J Hypertens. 2011 Sep; 29(9):1829-36.
    View in: PubMed
  45. Skali H, Uno H, Levey AS, Inker LA, Pfeffer MA, Solomon SD. Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation. Am Heart J. 2011 Sep; 162(3):548-54.
    View in: PubMed
  46. Desai AS, Toto R, Jarolim P, Uno H, Eckardt KU, Kewalramani R, Levey AS, Lewis EF, McMurray JJ, Parving HH, Solomon SD, Pfeffer MA. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J Kidney Dis. 2011 Nov; 58(5):717-28.
    View in: PubMed
  47. Penn J, Goldenberg I, Moss AJ, McNitt S, Zareba W, Klein HU, Cannom DS, Solomon SD, Barsheshet A, Huang DT. Improved outcome with preventive cardiac resynchronization therapy in the elderly: a MADIT-CRT substudy. J Cardiovasc Electrophysiol. 2011 Aug; 22(8):892-7.
    View in: PubMed
  48. Sidik NP, Solomon SD, Latini R, Maggioni AP, Wright M, Gimpelewicz CR, Pitt B, McMurray JJ. Effect of aliskiren in patients with heart failure according to background dose of ACE inhibitor: a retrospective analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) trial. Cardiovasc Drugs Ther. 2011 Aug; 25(4):315-21.
    View in: PubMed
  49. O'Donoghue ML, Mallat Z, Morrow DA, Benessiano J, Sloan S, Omland T, Solomon SD, Braunwald E, Tedgui A, Sabatine MS. Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease. Clin Chem. 2011 Sep; 57(9):1311-7.
    View in: PubMed
  50. Pouleur AC, Uno H, Prescott MF, Desai A, Appelbaum E, Lukashevich V, Smith BA, Dahlöf B, Solomon SD. Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension. J Renin Angiotensin Aldosterone Syst. 2011 Dec; 12(4):483-90.
    View in: PubMed
  51. Andersson C, Gislason GH, Mérie C, Mogensen UM, Solomon SD, Torp-Pedersen C, Køber L. Long-term prognostic importance of diabetes after a myocardial infarction depends on left ventricular systolic function. Diabetes Care. 2011 Aug; 34(8):1788-90.
    View in: PubMed
  52. Barsheshet A, Wang PJ, Moss AJ, Solomon SD, Al-Ahmad A, McNitt S, Foster E, Huang DT, Klein HU, Zareba W, Eldar M, Goldenberg I. Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy). J Am Coll Cardiol. 2011 Jun 14; 57(24):2416-23.
    View in: PubMed
  53. Pouleur AC, Knappe D, Shah AM, Uno H, Bourgoun M, Foster E, McNitt S, Hall WJ, Zareba W, Goldenberg I, Moss AJ, Pfeffer MA, Solomon SD. Relationship between improvement in left ventricular dyssynchrony and contractile function and clinical outcome with cardiac resynchronization therapy: the MADIT-CRT trial. Eur Heart J. 2011 Jul; 32(14):1720-9.
    View in: PubMed
  54. Ye S, Grunnert M, Thune JJ, Stephenson KM, Uno H, Finn PV, McMurray JJ, Velazquez EJ, Califf R, Pfeffer MA, Solomon SD. Circumstances and outcomes of sudden unexpected death in patients with high-risk myocardial infarction: implications for prevention. Circulation. 2011 Jun 14; 123(23):2674-80.
    View in: PubMed
  55. Knappe D, Pouleur AC, Shah AM, Cheng S, Uno H, Hall WJ, Bourgoun M, Foster E, Zareba W, Goldenberg I, McNitt S, Pfeffer MA, Moss AJ, Solomon SD. Dyssynchrony, contractile function, and response to cardiac resynchronization therapy. Circ Heart Fail. 2011 Jul; 4(4):433-40.
    View in: PubMed
  56. Verma A, Pfeffer MA, Skali H, Rouleau J, Maggioni A, McMurray JJ, Califf RM, Velazquez EJ, Solomon SD. Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarction. Am Heart J. 2011 Jun; 161(6):1156-62.
    View in: PubMed
  57. Vardeny O, Uno H, Braunwald E, Rouleau JL, Gersh B, Maggioni AP, Domanski M, Pfeffer MA, Solomon SD. Opposing effects of ß blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease. Am J Cardiol. 2011 Jun 15; 107(12):1705-9.
    View in: PubMed
  58. Bostom AG, Carpenter MA, Kusek JW, Levey AS, Hunsicker L, Pfeffer MA, Selhub J, Jacques PF, Cole E, Gravens-Mueller L, House AA, Kew C, McKenney JL, Pacheco-Silva A, Pesavento T, Pirsch J, Smith S, Solomon S, Weir M. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. Circulation. 2011 Apr 26; 123(16):1763-70.
    View in: PubMed
  59. Pitt B, Latini R, Maggioni AP, Solomon SD, Smith BA, Wright M, Prescott MF, McMurray JJ. Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. Eur J Heart Fail. 2011 Jul; 13(7):755-64.
    View in: PubMed
  60. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens. 2011 Apr; 29(4):623-35.
    View in: PubMed
  61. Jackson CE, MacDonald MR, Petrie MC, Solomon SD, Pitt B, Latini R, Maggioni AP, Smith BA, Prescott MF, Lewsey J, McMurray JJ. Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. Eur J Heart Fail. 2011 Jul; 13(7):746-54.
    View in: PubMed
  62. Pritchett Y, Jemiai Y, Chang Y, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata-Andía JB, Thompson T, Appelbaum E, Audhya P, Andress D, Zhang W, Solomon S, Manning WJ, Thadhani R. The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease. Clin Trials. 2011 Apr; 8(2):165-74.
    View in: PubMed
  63. Zareba W, Klein H, Cygankiewicz I, Hall WJ, McNitt S, Brown M, Cannom D, Daubert JP, Eldar M, Gold MR, Goldberger JJ, Goldenberg I, Lichstein E, Pitschner H, Rashtian M, Solomon S, Viskin S, Wang P, Moss AJ. Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation. 2011 Mar 15; 123(10):1061-72.
    View in: PubMed
  64. Arshad A, Moss AJ, Foster E, Padeletti L, Barsheshet A, Goldenberg I, Greenberg H, Hall WJ, McNitt S, Zareba W, Solomon S, Steinberg JS. Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. J Am Coll Cardiol. 2011 Feb 15; 57(7):813-20.
    View in: PubMed
  65. Solomon SD, Shin SH, Shah A, Skali H, Desai A, Kober L, Maggioni AP, Rouleau JL, Kelly RY, Hester A, McMurray JJ, Pfeffer MA. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J. 2011 May; 32(10):1227-34.
    View in: PubMed
  66. Thadhani R, Appelbaum E, Chang Y, Pritchett Y, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson T, Audhya P, Andress D, Zhang W, Ye J, Packham D, Singh B, Zehnder D, Manning WJ, Pachika A, Solomon SD. Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease. Am J Nephrol. 2011; 33(2):139-49.
    View in: PubMed
  67. Lewis EF, Pfeffer MA, Feng A, Uno H, McMurray JJ, Toto R, Gandra SR, Solomon SD, Moustafa M, Macdougall IC, Locatelli F, Parfrey PS. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clin J Am Soc Nephrol. 2011 Apr; 6(4):845-55.
    View in: PubMed
  68. Hung CL, Verma A, Uno H, Shin SH, Bourgoun M, Hassanein AH, McMurray JJ, Velazquez EJ, Kober L, Pfeffer MA, Solomon SD. Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction. J Am Coll Cardiol. 2010 Nov 23; 56(22):1812-22.
    View in: PubMed
  69. Shah AM, Uno H, Køber L, Velazquez EJ, Maggioni AP, MacDonald MR, Petrie MC, McMurray JJ, Califf RM, Pfeffer MA, Solomon SD. The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction. Eur J Heart Fail. 2010 Nov; 12(11):1229-37.
    View in: PubMed
  70. Thune JJ, Signorovitch JE, Kober L, McMurray JJ, Swedberg K, Rouleau J, Maggioni A, Velazquez E, Califf R, Pfeffer MA, Solomon SD. Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. Eur J Heart Fail. 2011 Feb; 13(2):148-53.
    View in: PubMed
  71. Chung ES, Dan D, Solomon SD, Bank AJ, Pastore J, Iyer A, Berger RD, Franklin JO, Jones G, Machado C, Stolen CM. Effect of peri-infarct pacing early after myocardial infarction: results of the prevention of myocardial enlargement and dilatation post myocardial infarction study. Circ Heart Fail. 2010 Nov; 3(6):650-8.
    View in: PubMed
  72. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010 Sep 16; 363(12):1146-55.
    View in: PubMed
  73. Goldenberg I, Moss AJ, McNitt S, Barsheshet A, Gray D, Andrews ML, Brown MW, Zareba W, Sze E, Solomon SD, Pfeffer MA. Relation between renal function and response to cardiac resynchronization therapy in Multicenter Automatic Defibrillator Implantation Trial--Cardiac Resynchronization Therapy (MADIT-CRT). Heart Rhythm. 2010 Dec; 7(12):1777-82.
    View in: PubMed
  74. Solomon SD, Foster E, Bourgoun M, Shah A, Viloria E, Brown MW, Hall WJ, Pfeffer MA, Moss AJ. Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: multicenter automatic defibrillator implantation trial: cardiac resynchronization therapy. Circulation. 2010 Sep 7; 122(10):985-92.
    View in: PubMed
  75. Shah AM, Pfeffer MA, Hartley LH, Moyé LA, Gersh BJ, Rutherford JD, Lamas GA, Rouleau JL, Braunwald E, Solomon SD. Risk of all-cause mortality, recurrent myocardial infarction, and heart failure hospitalization associated with smoking status following myocardial infarction with left ventricular dysfunction. Am J Cardiol. 2010 Oct 1; 106(7):911-6.
    View in: PubMed
  76. Shah AM, Solomon SD. A unified view of ventricular remodelling. Eur J Heart Fail. 2010 Aug; 12(8):779-81.
    View in: PubMed
  77. Pouleur AC, Barkoudah E, Uno H, Skali H, Finn PV, Zelenkofske SL, Belenkov YN, Mareev V, Velazquez EJ, Rouleau JL, Maggioni AP, Køber L, Califf RM, McMurray JJ, Pfeffer MA, Solomon SD. Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. Circulation. 2010 Aug 10; 122(6):597-602.
    View in: PubMed
  78. Shamshad F, Kenchaiah S, Finn PV, Soler-Soler J, McMurray JJ, Velazquez EJ, Maggioni AP, Califf RM, Swedberg K, Kober L, Belenkov Y, Varshavsky S, Pfeffer MA, Solomon SD. Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT). Am Heart J. 2010 Jul; 160(1):145-51.
    View in: PubMed
  79. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010 Jul; 23(7):685-713; quiz 786-8.
    View in: PubMed
  80. Sampson UK, Metcalfe C, Pfeffer MA, Solomon SD, Zou KH. Composite outcomes: weighting component events according to severity assisted interpretation but reduced statistical power. J Clin Epidemiol. 2010 Oct; 63(10):1156-8.
    View in: PubMed
  81. Solomon SD. Cardiovascular clinical trials in patients with diabetes mellitus: lessons from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study. Circulation. 2010 Jun 8; 121(22):2453-5.
    View in: PubMed
  82. Desai A, Lewis E, Solomon S, McMurray JJ, Pfeffer M. Impact of erythropoiesis-stimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT meta-analysis. Eur J Heart Fail. 2010 Sep; 12(9):936-42.
    View in: PubMed
  83. Partington SL, Ali B, Daly RP, Koplan BA, Lilly LS, Solomon SD, Kwong RY, Blankstein R. Images in cardiovascular medicine. Initial presentation of an accessory left ventricle in a patient with syncope. Circulation. 2010 May 18; 121(19):e401-3.
    View in: PubMed
  84. Chang SM, Granger CB, Johansson PA, Kosolcharoen P, McMurray JJ, Michelson EL, Murray DR, Olofsson B, Pfeffer MA, Solomon SD, Swedberg K, Yusuf S, Dunlap ME. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Fail. 2010 Jul; 12(7):738-45.
    View in: PubMed
  85. Hawkins NM, Wang D, Petrie MC, Pfeffer MA, Swedberg K, Granger CB, Yusuf S, Solomon SD, Ostergren J, Michelson EL, Pocock SJ, Maggioni AP, McMurray JJ. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. Eur J Heart Fail. 2010 Jun; 12(6):557-65.
    View in: PubMed
  86. Shin SH, Hung CL, Uno H, Hassanein AH, Verma A, Bourgoun M, Køber L, Ghali JK, Velazquez EJ, Califf RM, Pfeffer MA, Solomon SD. Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both. Circulation. 2010 Mar 9; 121(9):1096-103.
    View in: PubMed
  87. Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010 Apr 3; 375(9721):1173-81.
    View in: PubMed
  88. Wu JC, Ho CY, Skali H, Abichandani R, Wilcox WR, Banikazemi M, Packman S, Sims K, Solomon SD. Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity. Eur Heart J. 2010 May; 31(9):1088-97.
    View in: PubMed
  89. Solomon SD, Verma A, Desai A, Hassanein A, Izzo J, Oparil S, Lacourciere Y, Lee J, Seifu Y, Hilkert RJ, Rocha R, Pitt B. Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. Hypertension. 2010 Feb; 55(2):241-8.
    View in: PubMed
  90. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009 Nov 19; 361(21):2019-32.
    View in: PubMed
  91. Piccini JP, Zhang M, Pieper K, Solomon SD, Al-Khatib SM, Van de Werf F, Pfeffer MA, McMurray JJ, Califf RM, Velazquez EJ. Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. Eur Heart J. 2010 Jan; 31(2):211-21.
    View in: PubMed
  92. Bex PJ, Solomon SG, Dakin SC. Contrast sensitivity in natural scenes depends on edge as well as spatial frequency structure. J Vis. 2009; 9(10):1.1-19.
    View in: PubMed
  93. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009 Oct 1; 361(14):1329-38.
    View in: PubMed
  94. Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, Granger CB, Swedberg K, Pfeffer MA, Yusuf S, McMurray JJ. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet. 2009 Aug 15; 374(9689):543-50.
    View in: PubMed
  95. Janardhanan R, Desai AS, Solomon SD. Therapeutic approaches to diastolic dysfunction. Curr Hypertens Rep. 2009 Aug; 11(4):283-91.
    View in: PubMed
  96. Venditti EM, Elliot DL, Faith MS, Firrell LS, Giles CM, Goldberg L, Marcus MD, Schneider M, Solomon S, Thompson D, Yin Z. Rationale, design and methods of the HEALTHY study behavior intervention component. Int J Obes (Lond). 2009 Aug; 33 Suppl 4:S44-51.
    View in: PubMed
  97. McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, Polu KR, Solomon SD, Sun Y, Swedberg K, Tendera M, van Veldhuisen DJ, Wasserman SM, Young JB. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail. 2009 Aug; 11(8):795-801.
    View in: PubMed
  98. Hassanein A, Desai A, Verma A, Oparil S, Izzo J, Rocha R, Hilkert R, Seifu Y, Pitt B, Solomon S. EXCEED: Exforge-intensive control of hypertension to evaluate efficacy in diastolic dysfunction: study rationale, design, and participant characteristics. Ther Adv Cardiovasc Dis. 2009 Dec; 3(6):429-39.
    View in: PubMed
  99. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Pfeffer MA. Dual renin-angiotensin system blockade and kidney disease. J Am Coll Cardiol. 2009 Jul 14; 54(3):278-9; author reply 279-80.
    View in: PubMed
  100. Douglas PS, DeCara JM, Devereux RB, Duckworth S, Gardin JM, Jaber WA, Morehead AJ, Oh JK, Picard MH, Solomon SD, Wei K, Weissman NJ. Echocardiographic imaging in clinical trials: American Society of Echocardiography Standards for echocardiography core laboratories: endorsed by the American College of Cardiology Foundation. J Am Soc Echocardiogr. 2009 Jul; 22(7):755-65.
    View in: PubMed
  101. Moukarbel GV, Signorovitch JE, Pfeffer MA, McMurray JJ, White HD, Maggioni AP, Velazquez EJ, Califf RM, Scheiman JM, Solomon SD. Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. Eur Heart J. 2009 Sep; 30(18):2226-32.
    View in: PubMed
  102. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill J, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, Uno H. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2009 Jul; 54(1):59-69.
    View in: PubMed
  103. Verma A, Solomon SD. Diastolic dysfunction as a link between hypertension and heart failure. Med Clin North Am. 2009 May; 93(3):647-64.
    View in: PubMed
  104. Lewis EF, Solomon SD, Jablonski KA, Rice MM, Clemenza F, Hsia J, Maggioni AP, Zabalgoitia M, Huynh T, Cuddy TE, Gersh BJ, Rouleau J, Braunwald E, Pfeffer MA. Predictors of heart failure in patients with stable coronary artery disease: a PEACE study. Circ Heart Fail. 2009 May; 2(3):209-16.
    View in: PubMed
  105. Berry C, Pieper KS, White HD, Solomon SD, Van de Werf F, Velazquez EJ, Maggioni AP, Califf RM, Pfeffer MA, McMurray JJ. Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT). Eur Heart J. 2009 Jun; 30(12):1450-6.
    View in: PubMed
  106. Bertagnolli MM, Zauber AG, Solomon S. Prostaglandin inhibition and cardiovascular risk: maybe timing really is everything. Cancer Prev Res (Phila). 2009 Mar; 2(3):195-6.
    View in: PubMed
  107. Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velazquez EJ, Swedberg K, Pfeffer MA, McMurray JJ, Maggioni AP. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail. 2009 Mar; 11(3):292-8.
    View in: PubMed
  108. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif Papst C, Smith BA, Dahlöf B. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009 Feb 3; 119(4):530-7.
    View in: PubMed
  109. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant. 2009 May; 24(5):1663-71.
    View in: PubMed
  110. Solomon SD, Stevenson LW. Recalibrating the barometer: is it time to take a critical look at noninvasive approaches to measuring filling pressures? Circulation. 2009 Jan 6; 119(1):13-5.
    View in: PubMed
  111. Meredith PA, Ostergren J, Anand I, Puu M, Solomon SD, Michelson EL, Olofsson B, Granger CB, Yusuf S, Swedberg K, Pfeffer MA, McMurray JJ. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. J Am Coll Cardiol. 2008 Dec 9; 52(24):2000-7.
    View in: PubMed
  112. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008 Dec 4; 359(23):2417-28.
    View in: PubMed
  113. Moukarbel GV, Solomon SD. Treatment of asymptomatic left ventricular dysfunction. Curr Treat Options Cardiovasc Med. 2008 Dec; 10(6):476-85.
    View in: PubMed
  114. Moukarbel GV, Solomon SD. Early use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: evidence from clinical trials. Curr Heart Fail Rep. 2008 Dec; 5(4):197-203.
    View in: PubMed
  115. Abrahamsson P, Dobson J, Granger CB, McMurray JJ, Michelson EL, Pfeffer M, Pocock S, Solomon SD, Yusuf S, Swedberg K. Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. Eur Heart J. 2009 Feb; 30(3):338-45.
    View in: PubMed
  116. Meris A, Amigoni M, Uno H, Thune JJ, Verma A, Køber L, Bourgoun M, McMurray JJ, Velazquez EJ, Maggioni AP, Ghali J, Arnold JM, Zelenkofske S, Pfeffer MA, Solomon SD. Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo study. Eur Heart J. 2009 Jan; 30(1):56-65.
    View in: PubMed
  117. Cohen-Solal A, McMurray JJ, Swedberg K, Pfeffer MA, Puu M, Solomon SD, Michelson EL, Yusuf S, Granger CB. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. Eur Heart J. 2008 Dec; 29(24):3022-8.
    View in: PubMed
  118. Vardeny O, Solomon SD. Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk. Cardiol Clin. 2008 Nov; 26(4):589-601.
    View in: PubMed
  119. Solomon S, Affan AM, Gopie P, Noel J, Rahman R, Richardson R, Ramkisson S, Mungrue K, Hasranah D, Naraynsingh V. Taking the next step in 2005, the year of the diabetic foot. Prim Care Diabetes. 2008 Dec; 2(4):175-80.
    View in: PubMed
  120. Pocock SJ, McMurray JJ, Dobson J, Yusuf S, Granger CB, Michelson EL, Ostergren J, Pfeffer MA, Solomon SD, Anker SD, Swedberg KB. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J. 2008 Nov; 29(21):2641-50.
    View in: PubMed
  121. Piccini JP, Hranitzky PM, Kilaru R, Rouleau JL, White HD, Aylward PE, Van de Werf F, Solomon SD, Califf RM, Velazquez EJ. Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry). Am J Cardiol. 2008 Dec 1; 102(11):1427-32.
    View in: PubMed
  122. Verma A, Meris A, Skali H, Ghali JK, Arnold JM, Bourgoun M, Velazquez EJ, McMurray JJ, Kober L, Pfeffer MA, Califf RM, Solomon SD. Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC Cardiovasc Imaging. 2008 Sep; 1(5):582-91.
    View in: PubMed
  123. Tardif JC, McMurray JJ, Klug E, Small R, Schumi J, Choi J, Cooper J, Scott R, Lewis EF, L'Allier PL, Pfeffer MA. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2008 May 24; 371(9626):1761-8.
    View in: PubMed
  124. McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma A, Lewsey J. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008 May; 1(1):17-24.
    View in: PubMed
  125. MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray JJ. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008 Jun; 29(11):1377-85.
    View in: PubMed
  126. Weinrauch LA, Lin J, Solomon SD. Mapping directions for the cardiorenal conundrum: where you end up depends upon where you started, so where do we go from here? J Am Coll Cardiol. 2008 Apr 1; 51(13):1275-6.
    View in: PubMed
  127. Anavekar NS, Solomon SD, McMurray JJ, Maggioni A, Rouleau JL, Califf R, White H, Kober L, Velazquez E, Pfeffer MA. Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus. Am J Cardiol. 2008 Apr 1; 101(7):925-9.
    View in: PubMed
  128. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008 Apr 22; 117(16):2104-13.
    View in: PubMed
  129. Anavekar NS, Skali H, Bourgoun M, Ghali JK, Kober L, Maggioni AP, McMurray JJ, Velazquez E, Califf R, Pfeffer MA, Solomon SD. Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO Study). Am J Cardiol. 2008 Mar 1; 101(5):607-12.
    View in: PubMed
  130. Lewis EF, Velazquez EJ, Solomon SD, Hellkamp AS, McMurray JJ, Mathias J, Rouleau JL, Maggioni AP, Swedberg K, Kober L, White H, Dalby AJ, Francis GS, Zannad F, Califf RM, Pfeffer MA. Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. Eur Heart J. 2008 Mar; 29(6):748-56.
    View in: PubMed
  131. Anderson RE, Pfeffer MA, Thune JJ, McMurray JJ, Califf RM, Velazquez E, White HD, Rouleau JL, Skali H, Maggioni A, Solomon SD. High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Am Heart J. 2008 Apr; 155(4):706-11.
    View in: PubMed
  132. Weir RA, McMurray JJ, Puu M, Solomon SD, Olofsson B, Granger CB, Yusuf S, Michelson EL, Swedberg K, Pfeffer MA. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Eur J Heart Fail. 2008 Feb; 10(2):157-63.
    View in: PubMed
  133. Solomon SD. Atlas of Echocardiography. 2008.
  134. Verma A, Solomon SD. Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist. Curr Heart Fail Rep. 2007 Dec; 4(4):183-9.
    View in: PubMed
  135. Thune JJ, Signorovitch J, Kober L, Velazquez EJ, McMurray JJ, Califf RM, Maggioni AP, Rouleau JL, Howlett J, Zelenkofske S, Pfeffer MA, Solomon SD. Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. Hypertension. 2008 Jan; 51(1):48-54.
    View in: PubMed
  136. Solomon SD, Lin J, Solomon CG, Jablonski KA, Rice MM, Steffes M, Domanski M, Hsia J, Gersh BJ, Arnold JM, Rouleau J, Braunwald E, Pfeffer MA. Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease. Circulation. 2007 Dec 4; 116(23):2687-93.
    View in: PubMed
  137. Desai AS, Swedberg K, McMurray JJ, Granger CB, Yusuf S, Young JB, Dunlap ME, Solomon SD, Hainer JW, Olofsson B, Michelson EL, Pfeffer MA. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. J Am Coll Cardiol. 2007 Nov 13; 50(20):1959-66.
    View in: PubMed
  138. Verma A, Anavekar NS, Meris A, Thune JJ, Arnold JM, Ghali JK, Velazquez EJ, McMurray JJ, Pfeffer MA, Solomon SD. The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction: the VALIANT Echo Study. J Am Coll Cardiol. 2007 Sep 25; 50(13):1238-45.
    View in: PubMed
  139. Ounis-Skali N, Bentley-Lewis R, Mitchell GF, Solomon S, Seely EW. Central aortic pulsatile hemodynamics in obese premenopausal women. J Am Soc Hypertens. 2007 Sep-Oct; 1(5):341-6.
    View in: PubMed
  140. Sabatine MS, Morrow DA, O'Donoghue M, Jablonksi KA, Rice MM, Solomon S, Rosenberg Y, Domanski MJ, Hsia J. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol. 2007 Nov; 27(11):2463-9.
    View in: PubMed
  141. Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, Yusuf S, Swedberg K, Young JB, Michelson EL, Pfeffer MA. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007 Sep 25; 116(13):1482-7.
    View in: PubMed
  142. Kenchaiah S, Pocock SJ, Wang D, Finn PV, Zornoff LA, Skali H, Pfeffer MA, Yusuf S, Swedberg K, Michelson EL, Granger CB, McMurray JJ, Solomon SD. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2007 Aug 7; 116(6):627-36.
    View in: PubMed
  143. Mielniczuk LM, Lamas GA, Flaker GC, Mitchell G, Smith SC, Gersh BJ, Solomon SD, Moyé LA, Rouleau JL, Rutherford JD, Pfeffer MA. Left ventricular end-diastolic pressure and risk of subsequent heart failure in patients following an acute myocardial infarction. Congest Heart Fail. 2007 Jul-Aug; 13(4):209-14.
    View in: PubMed
  144. Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, Lacourcière Y, Hippler SE, Fields H, Naqvi TZ, Mulvagh SL, Arnold JM, Thomas JD, Zile MR, Aurigemma GP. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet. 2007 Jun 23; 369(9579):2079-87.
    View in: PubMed
  145. O'Meara E, Clayton T, McEntegart MB, McMurray JJ, Piña IL, Granger CB, Ostergren J, Michelson EL, Solomon SD, Pocock S, Yusuf S, Swedberg K, Pfeffer MA. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2007 Jun 19; 115(24):3111-20.
    View in: PubMed
  146. Anavekar NS, Gerson D, Skali H, Kwong RY, Yucel EK, Solomon SD. Two-dimensional assessment of right ventricular function: an echocardiographic-MRI correlative study. Echocardiography. 2007 May; 24(5):452-6.
    View in: PubMed
  147. Mitchell GF, Dunlap ME, Warnica W, Ducharme A, Arnold JM, Tardif JC, Solomon SD, Domanski MJ, Jablonski KA, Rice MM, Pfeffer MA. Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy. Hypertension. 2007 Jun; 49(6):1271-7.
    View in: PubMed
  148. Amigoni M, Meris A, Thune JJ, Mangalat D, Skali H, Bourgoun M, Warnica JW, Barvik S, Arnold JM, Velazquez EJ, Van de Werf F, Ghali J, McMurray JJ, Køber L, Pfeffer MA, Solomon SD. Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function. Eur Heart J. 2007 Feb; 28(3):326-33.
    View in: PubMed
  149. Thune JJ, Køber L, Pfeffer MA, Skali H, Anavekar NS, Bourgoun M, Ghali JK, Arnold JM, Velazquez EJ, Solomon SD. Comparison of regional versus global assessment of left ventricular function in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction: the valsartan in acute myocardial infarction echocardiographic study. J Am Soc Echocardiogr. 2006 Dec; 19(12):1462-5.
    View in: PubMed
  150. Thune JJ, Solomon SD. Left ventricular diastolic function following myocardial infarction. Curr Heart Fail Rep. 2006 Dec; 3(4):170-4.
    View in: PubMed
  151. Stephenson K, Skali H, McMurray JJ, Velazquez EJ, Aylward PG, Kober L, Van de Werf F, White HD, Pieper KS, Califf RM, Solomon SD, Pfeffer MA. Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience. Heart Rhythm. 2007 Mar; 4(3):308-13.
    View in: PubMed
  152. Skali H, Pfeffer MA, Lubsen J, Solomon SD. Variable impact of combining fatal and nonfatal end points in heart failure trials. Circulation. 2006 Nov 21; 114(21):2298-303.
    View in: PubMed
  153. Solomon SD. Cyclooxygenase-2 inhibitors and cardiovascular risk. Curr Opin Cardiol. 2006 Nov; 21(6):613-7.
    View in: PubMed
  154. Field ME, Solomon SD, Lewis EF, Kramer DB, Baughman KL, Stevenson LW, Tedrow UB. Right ventricular dysfunction and adverse outcome in patients with advanced heart failure. J Card Fail. 2006 Oct; 12(8):616-20.
    View in: PubMed
  155. Solomon SD. Is elevated cardiovascular risk a class effect of cyclo-oxygenase 2 inhibitors? Nat Clin Pract Cardiovasc Med. 2006 Oct; 3(10):532-3.
    View in: PubMed
  156. Sampson UK, Pfeffer MA, McMurray JJ, Lokhnygina Y, White HD, Solomon SD. Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT Trial. Eur Heart J. 2007 Mar; 28(6):685-91.
    View in: PubMed
  157. Noiseux N, Gnecchi M, Lopez-Ilasaca M, Zhang L, Solomon SD, Deb A, Dzau VJ, Pratt RE. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther. 2006 Dec; 14(6):840-50.
    View in: PubMed
  158. Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N, Wittes J. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006 Sep 5; 114(10):1028-35.
    View in: PubMed
  159. Ounis-Skali N, Mitchell GF, Solomon CG, Solomon SD, Seely EW. Changes in central arterial pressure waveforms during the normal menstrual cycle. J Investig Med. 2006 Sep; 54(6):321-6.
    View in: PubMed
  160. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006 Aug 31; 355(9):873-84.
    View in: PubMed
  161. Jose P, Skali H, Anavekar N, Tomson C, Krumholz HM, Rouleau JL, Moye L, Pfeffer MA, Solomon SD. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol. 2006 Oct; 17(10):2886-91.
    View in: PubMed
  162. Williams JS, Solomon SD, Crivaro M, Conlin PR. Dietary sodium intake modulates myocardial relaxation responsiveness to angiotensin II. Transl Res. 2006 Aug; 148(2):49-54.
    View in: PubMed
  163. Janardhanan R, Daley WL, Naqvi TZ, Mulvagh SL, Aurigemma G, Zile M, Arnold JM, Artis E, Purkayastha D, Thomas JD, Solomon SD. Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) Trial: evolving the management of diastolic dysfunction in hypertension. Am Heart J. 2006 Aug; 152(2):246-52.
    View in: PubMed
  164. Janardhanan R, Kenchaiah S, Velazquez EJ, Park Y, McMurray JJ, Weaver WD, Finn PV, White HD, Marin-Neto JA, O'Connor C, Pfeffer MA, Califf RM, Solomon SD. Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. Am Heart J. 2006 Jul; 152(1):183-9.
    View in: PubMed
  165. Tokmakova M, Solomon SD. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials. Curr Opin Cardiol. 2006 Jul; 21(4):268-72.
    View in: PubMed
  166. Solomon SD, Rice MM, A Jablonski K, Jose P, Domanski M, Sabatine M, Gersh BJ, Rouleau J, Pfeffer MA, Braunwald E. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation. 2006 Jul 4; 114(1):26-31.
    View in: PubMed
  167. Grosberg BM, Solomon S. Retinal migraine: two cases of prolonged but reversible monocular visual defects. Cephalalgia. 2006 Jun; 26(6):754-7.
    View in: PubMed
  168. Jose P, Tomson C, Skali H, Rouleau J, Braunwald E, Arnold JM, Cuddy T, Sussex B, Bernstein V, Pfeffer M, Solomon S. Influence of proteinuria on cardiovascular risk and response to angiotensin-converting enzyme inhibition after myocardial infarction. J Am Coll Cardiol. 2006 Apr 18; 47(8):1725-7.
    View in: PubMed
  169. Ho CY, Solomon SD. A clinician's guide to tissue Doppler imaging. Circulation. 2006 Mar 14; 113(10):e396-8.
    View in: PubMed
  170. Yerra L, Anavekar N, Skali H, Zelenkofske S, Velazquez E, McMurray J, Pfeffer M, Solomon SD. Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial. Heart Rhythm. 2006 Mar; 3(3):313-6.
    View in: PubMed
  171. Køber L, Swedberg K, McMurray JJ, Pfeffer MA, Velazquez EJ, Diaz R, Maggioni AP, Mareev V, Opolski G, Van de Werf F, Zannad F, Ertl G, Solomon SD, Zelenkofske S, Rouleau JL, Leimberger JD, Califf RM. Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. Eur J Heart Fail. 2006 Oct; 8(6):591-8.
    View in: PubMed
  172. O'Meara E, Clayton T, McEntegart MB, McMurray JJ, Lang CC, Roger SD, Young JB, Solomon SD, Granger CB, Ostergren J, Olofsson B, Michelson EL, Pocock S, Yusuf S, Swedberg K, Pfeffer MA. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation. 2006 Feb 21; 113(7):986-94.
    View in: PubMed
  173. McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol. 2006 Feb 21; 47(4):726-33.
    View in: PubMed
  174. Anavekar NS, Mirza A, Skali H, Plappert T, St John Sutton M, Pfeffer MA, Solomon SD. Risk assessment in patients with depressed left ventricular function after myocardial infarction using the myocardial performance index--Survival and Ventricular Enlargement (SAVE) experience. J Am Soc Echocardiogr. 2006 Jan; 19(1):28-33.
    View in: PubMed
  175. Yan AT, Gibson CM, Larose E, Anavekar NS, Tsang S, Solomon SD, Reynolds G, Kwong RY. Characterization of microvascular dysfunction after acute myocardial infarction by cardiovascular magnetic resonance first-pass perfusion and late gadolinium enhancement imaging. J Cardiovasc Magn Reson. 2006; 8(6):831-7.
    View in: PubMed
  176. Solomon SD, Anavekar N, Skali H, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Wang D, Pocock S, Pfeffer MA. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005 Dec 13; 112(24):3738-44.
    View in: PubMed
  177. Hernandez AF, Velazquez EJ, Solomon SD, Kilaru R, Diaz R, O'Connor CM, Ertl G, Maggioni AP, Rouleau JL, van Gilst W, Pfeffer MA, Califf RM. Left ventricular assessment in myocardial infarction: the VALIANT registry. Arch Intern Med. 2005 Oct 10; 165(18):2162-9.
    View in: PubMed
  178. Skali H, Zornoff LA, Pfeffer MA, Arnold MO, Lamas GA, Moyé LA, Plappert T, Rouleau JL, Sussex BA, St John Sutton M, Braunwald E, Solomon SD. Prognostic use of echocardiography 1 year after a myocardial infarction. Am Heart J. 2005 Oct; 150(4):743-9.
    View in: PubMed
  179. Solomon SD, Skali H, Bourgoun M, Fang J, Ghali JK, Martelet M, Wojciechowski D, Ansmite B, Skards J, Laks T, Henry D, Packer M, Pfeffer MA. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study. Am Heart J. 2005 Aug; 150(2):257-62.
    View in: PubMed
  180. Scridon T, Scridon C, Skali H, Alvarez A, Goldhaber SZ, Solomon SD. Prognostic significance of troponin elevation and right ventricular enlargement in acute pulmonary embolism. Am J Cardiol. 2005 Jul 15; 96(2):303-5.
    View in: PubMed
  181. Walsh MC, Bourcier T, Takahashi K, Shi L, Busche MN, Rother RP, Solomon SD, Ezekowitz RA, Stahl GL. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J Immunol. 2005 Jul 1; 175(1):541-6.
    View in: PubMed
  182. Solomon SD, Zelenkofske S, McMurray JJ, Finn PV, Velazquez E, Ertl G, Harsanyi A, Rouleau JL, Maggioni A, Kober L, White H, Van de Werf F, Pieper K, Califf RM, Pfeffer MA. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005 Jun 23; 352(25):2581-8.
    View in: PubMed
  183. Szummer KE, Solomon SD, Velazquez EJ, Kilaru R, McMurray J, Rouleau JL, Mahaffey KW, Maggioni AP, Califf RM, Pfeffer MA, White HD. Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. Eur Heart J. 2005 Oct; 26(20):2114-9.
    View in: PubMed
  184. Solomon SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK, Warnica JW, Khrakovskaya M, Arnold JM, Schwartz Y, Velazquez EJ, Califf RM, McMurray JV, Pfeffer MA. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation. 2005 Jun 28; 111(25):3411-9.
    View in: PubMed
  185. Mix TC, Brenner RM, Cooper ME, de Zeeuw D, Ivanovich P, Levey AS, McGill JB, McMurray JJ, Parfrey PS, Parving HH, Pereira BJ, Remuzzi G, Singh AK, Solomon SD, Stehman-Breen C, Toto RD, Pfeffer MA. Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J. 2005 Mar; 149(3):408-13.
    View in: PubMed
  186. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005 Mar 17; 352(11):1071-80.
    View in: PubMed
  187. Pfeffer MA, Solomon SD, Singh AK, Ivanovich P, McMurray JJ. Uncertainty in the treatment of anemia in chronic kidney disease. Rev Cardiovasc Med. 2005; 6 Suppl 3:S35-41.
    View in: PubMed
  188. Tokmakova MP, Skali H, Kenchaiah S, Braunwald E, Rouleau JL, Packer M, Chertow GM, Moyé LA, Pfeffer MA, Solomon SD. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. Circulation. 2004 Dec 14; 110(24):3667-73.
    View in: PubMed
  189. O'Meara E, Solomon S, McMurray J, Pfeffer M, Yusuf S, Michelson E, Granger C, Olofsson B, Young JB, Swedberg K. Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2004 Nov; 25(21):1920-6.
    View in: PubMed
  190. Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, Hradec J, Kuch J, McKelvie RS, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Held P, Solomon SD, Yusuf S, Swedberg K. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation. 2004 Oct 26; 110(17):2618-26.
    View in: PubMed
  191. Solomon SD, Wang D, Finn P, Skali H, Zornoff L, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Pocock S, Pfeffer MA. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2004 Oct 12; 110(15):2180-3.
    View in: PubMed
  192. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004 Sep 23; 351(13):1285-95.
    View in: PubMed
  193. Aguilar D, Solomon SD, Køber L, Rouleau JL, Skali H, McMurray JJ, Francis GS, Henis M, O'Connor CM, Diaz R, Belenkov YN, Varshavsky S, Leimberger JD, Velazquez EJ, Califf RM, Pfeffer MA. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation. 2004 Sep 21; 110(12):1572-8.
    View in: PubMed
  194. Pachori AS, Melo LG, Hart ML, Noiseux N, Zhang L, Morello F, Solomon SD, Stahl GL, Pratt RE, Dzau VJ. Hypoxia-regulated therapeutic gene as a preemptive treatment strategy against ischemia/reperfusion tissue injury. Proc Natl Acad Sci U S A. 2004 Aug 17; 101(33):12282-7.
    View in: PubMed
  195. Kenchaiah S, Pfeffer MA, St John Sutton M, Plappert T, Rouleau JL, Lamas GA, Sasson Z, Parker JO, Geltman EM, Solomon SD. Effect of antecedent systemic hypertension on subsequent left ventricular dilation after acute myocardial infarction (from the Survival and Ventricular Enlargement trial). Am J Cardiol. 2004 Jul 1; 94(1):1-8.
    View in: PubMed
  196. Aguilar D, Skali H, Moyé LA, Lewis EF, Gaziano JM, Rutherford JD, Hartley LH, Randall OS, Geltman EM, Lamas GA, Rouleau JL, Pfeffer MA, Solomon SD. Alcohol consumption and prognosis in patients with left ventricular systolic dysfunction after a myocardial infarction. J Am Coll Cardiol. 2004 Jun 2; 43(11):2015-21.
    View in: PubMed
  197. Quiroz R, Kucher N, Schoepf UJ, Kipfmueller F, Solomon SD, Costello P, Goldhaber SZ. Right ventricular enlargement on chest computed tomography: prognostic role in acute pulmonary embolism. Circulation. 2004 May 25; 109(20):2401-4.
    View in: PubMed
  198. Solomon SD, Anavekar NS, Greaves S, Rouleau JL, Hennekens C, Pfeffer MA. Angina pectoris prior to myocardial infarction protects against subsequent left ventricular remodeling. J Am Coll Cardiol. 2004 May 5; 43(9):1511-4.
    View in: PubMed
  199. Solomon SD. Essential Echocardiography. 2004.
  200. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003 Nov 13; 349(20):1893-906.
    View in: PubMed
  201. Solomon SD, Pfeffer MA. Aldosterone antagonism and myocardial infarction: from animals to man and back. J Am Coll Cardiol. 2003 Nov 5; 42(9):1674-6.
    View in: PubMed
  202. Jilaihawi H, Greaves S, Rouleau JL, Pfeffer MA, Solomon SD. Left ventricular hypertrophy and the risk of subsequent left ventricular remodeling following myocardial infarction. Am J Cardiol. 2003 Mar 15; 91(6):723-6.
    View in: PubMed
  203. Manes C, Pfeffer MA, Rutherford JD, Greaves S, Rouleau JL, Arnold JM, Menapace F, Solomon SD. Value of the electrocardiogram in predicting left ventricular enlargement and dysfunction after myocardial infarction. Am J Med. 2003 Feb 1; 114(2):99-105.
    View in: PubMed
  204. Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, Rouleau JL, Lee RT. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002 Dec 3; 106(23):2961-6.
    View in: PubMed
  205. Khan HH, Maisel WH, Ho C, Suzuki M, Soejima K, Solomon S, Stevenson WG. Effect of radiofrequency catheter ablation of ventricular tachycardia on left ventricular function in patients with prior myocardial infarction. J Interv Card Electrophysiol. 2002 Dec; 7(3):243-7.
    View in: PubMed
  206. Solomon SD, St John Sutton M, Lamas GA, Plappert T, Rouleau JL, Skali H, Moyé L, Braunwald E, Pfeffer MA. Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction. Circulation. 2002 Sep 3; 106(10):1251-5.
    View in: PubMed
  207. Nakamura R, Cortez K, Solomon S, Battiwalla M, Gill VJ, Hensel N, Childs R, Barrett AJ. High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant. 2002 Aug; 30(4):235-42.
    View in: PubMed
  208. Ho CY, Sweitzer NK, McDonough B, Maron BJ, Casey SA, Seidman JG, Seidman CE, Solomon SD. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation. 2002 Jun 25; 105(25):2992-7.
    View in: PubMed
  209. Zornoff LA, Skali H, Pfeffer MA, St John Sutton M, Rouleau JL, Lamas GA, Plappert T, Rouleau JR, Moyé LA, Lewis SJ, Braunwald E, Solomon SD. Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. J Am Coll Cardiol. 2002 May 1; 39(9):1450-5.
    View in: PubMed
  210. Zee RY, Solomon SD, Ajani UA, Pfeffer MA, Lindpaintner K. A prospective evaluation of the angiotensin-converting enzyme D/I polymorphism and left ventricular remodeling in the 'Healing and Early Afterload Reducing Therapy' study. Clin Genet. 2002 Jan; 61(1):21-5.
    View in: PubMed
  211. Holberg CJ, Halonen M, Solomon S, Graves PE, Baldini M, Erickson RP, Martinez FD. Factor analysis of asthma and atopy traits shows 2 major components, one of which is linked to markers on chromosome 5q. J Allergy Clin Immunol. 2001 Nov; 108(5):772-80.
    View in: PubMed
  212. Solomon S. Posttraumatic headache. Med Clin North Am. 2001 Jul; 85(4):987-96, vii-viii.
    View in: PubMed
  213. Solomon SD. Beyond remodeling: a new paradigm for angiotensin-converting enzyme inhibitors following myocardial infarction. J Cardiovasc Pharmacol. 2001 Apr; 37 Suppl 1:S31-4.
    View in: PubMed
  214. Solomon SD, Glynn RJ, Greaves S, Ajani U, Rouleau JL, Menapace F, Arnold JM, Hennekens C, Pfeffer MA. Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study. Ann Intern Med. 2001 Mar 20; 134(6):451-8.
    View in: PubMed
  215. Aikawa Y, Rohde L, Plehn J, Greaves SC, Menapace F, Arnold MO, Rouleau JL, Pfeffer MA, Lee RT, Solomon SD. Regional wall stress predicts ventricular remodeling after anteroseptal myocardial infarction in the Healing and Early Afterload Reducing Trial (HEART): an echocardiography-based structural analysis. Am Heart J. 2001 Feb; 141(2):234-42.
    View in: PubMed
  216. Kamisago M, Sharma SD, DePalma SR, Solomon S, Sharma P, McDonough B, Smoot L, Mullen MP, Woolf PK, Wigle ED, Seidman JG, Seidman CE. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med. 2000 Dec 7; 343(23):1688-96.
    View in: PubMed
  217. Solomon SD, Greaves SC, Rayan M, Finn P, Pfeffer MA, Pfeffer JM. Temporal dissociation of left ventricular function and remodeling following experimental myocardial infarction in rats. J Card Fail. 1999 Sep; 5(3):213-23.
    View in: PubMed
  218. Siu BL, Niimura H, Osborne JA, Fatkin D, MacRae C, Solomon S, Benson DW, Seidman JG, Seidman CE. Familial dilated cardiomyopathy locus maps to chromosome 2q31. Circulation. 1999 Mar 2; 99(8):1022-6.
    View in: PubMed
  219. Rohde LE, Aikawa M, Cheng GC, Sukhova G, Solomon SD, Libby P, Pfeffer J, Pfeffer MA, Lee RT. Echocardiography-derived left ventricular end-systolic regional wall stress and matrix remodeling after experimental myocardial infarction. J Am Coll Cardiol. 1999 Mar; 33(3):835-42.
    View in: PubMed
  220. Nass N, McConnell MV, Goldhaber SZ, Chyu S, Solomon SD. Recovery of regional right ventricular function after thrombolysis for pulmonary embolism. Am J Cardiol. 1999 Mar 1; 83(5):804-6, A10.
    View in: PubMed
  221. Solomon S, Kurian N, Ramadas P, Rao PS. Incidence of nerve damage in leprosy patients treated with MDT. Int J Lepr Other Mycobact Dis. 1998 Dec; 66(4):451-6.
    View in: PubMed
  222. Solomon SD, Aikawa Y, Martini MS, Rosario L, Makker G, Gerson D, Greaves S, Lee RT. Assessment of regional left ventricular wall stress after myocardial infarction by echocardiography-based structural analysis. J Am Soc Echocardiogr. 1998 Oct; 11(10):938-47.
    View in: PubMed
  223. Pfeffer MA, Greaves SC, Arnold JM, Glynn RJ, LaMotte FS, Lee RT, Menapace FJ, Rapaport E, Ridker PM, Rouleau JL, Solomon SD, Hennekens CH. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation. 1997 Jun 17; 95(12):2643-51.
    View in: PubMed
  224. Solomon SD, Pfeffer MA. The decreasing incidence of left ventricular remodeling following myocardial infarction. Basic Res Cardiol. 1997 Apr; 92(2):61-5.
    View in: PubMed
  225. Solomon SD, Davidson JR. Trauma: prevalence, impairment, service use, and cost. J Clin Psychiatry. 1997; 58 Suppl 9:5-11.
    View in: PubMed
  226. Ebenezer M, Partheebarajan S, Solomon S. Long-term follow-up of joint stabilization procedures in the treatment of fixed deformities of feet in leprosy. Lepr Rev. 1996 Jun; 67(2):126-34.
    View in: PubMed
  227. Basson CT, Cowley GS, Solomon SD, Weissman B, Poznanski AK, Traill TA, Seidman JG, Seidman CE. The clinical and genetic spectrum of the Holt-Oram syndrome (heart-hand syndrome) N Engl J Med. 1994 Mar 31; 330(13):885-91.
    View in: PubMed
  228. Anan R, Greve G, Thierfelder L, Watkins H, McKenna WJ, Solomon S, Vecchio C, Shono H, Nakao S, Tanaka H, et al. Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest. 1994 Jan; 93(1):280-5.
    View in: PubMed
  229. Solomon SD, Ridker PM, Antman EM. Ventricular arrhythmias in trials of thrombolytic therapy for acute myocardial infarction. A meta-analysis. Circulation. 1993 Dec; 88(6):2575-81.
    View in: PubMed
  230. Solomon SD, Wolff S, Jarboe LA, Wolfe MM, Lee RT. Effects of histamine type 2-receptor antagonists cimetidine and famotidine on left ventricular systolic function in chronic congestive heart failure. Am J Cardiol. 1993 Nov 15; 72(15):1163-6.
    View in: PubMed
  231. Delfino RJ, Ernst P, Jaakkola MS, Solomon S, Becklake MR. Questionnaire assessments of recent exposure to environmental tobacco smoke in relation to salivary cotinine. Eur Respir J. 1993 Sep; 6(8):1104-8.
    View in: PubMed
  232. Solomon SD, Wolff S, Watkins H, Ridker PM, Come P, McKenna WJ, Seidman CE, Lee RT. Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene. J Am Coll Cardiol. 1993 Aug; 22(2):498-505.
    View in: PubMed
  233. Sadro LC, Tremblay A, Solomon S, Palfree RG. Differential expression of corticostatins/defensins: higher levels of CS-4 (NP-2) transcripts compared with CS-6 (NP-5) in rabbit lung. Biochem Biophys Res Commun. 1993 Feb 15; 190(3):1009-16.
    View in: PubMed
  234. Solomon SD, Gerrity ET, Muff AM. Efficacy of treatments for posttraumatic stress disorder. An empirical review. JAMA. 1992 Aug 5; 268(5):633-8.
    View in: PubMed
  235. Robinson P, Bateman A, Mulay S, Spencer SJ, Jaffe RB, Solomon S, Bennett HP. Isolation and characterization of three forms of joining peptide from adult human pituitaries: lack of adrenal androgen-stimulating activity. Endocrinology. 1991 Aug; 129(2):859-67.
    View in: PubMed
  236. Tanigawa G, Jarcho JA, Kass S, Solomon SD, Vosberg HP, Seidman JG, Seidman CE. A molecular basis for familial hypertrophic cardiomyopathy: an alpha/beta cardiac myosin heavy chain hybrid gene. Cell. 1990 Sep 7; 62(5):991-8.
    View in: PubMed
  237. Solomon SD, Jarcho JA, McKenna W, Geisterfer-Lowrance A, Germain R, Salerni R, Seidman JG, Seidman CE. Familial hypertrophic cardiomyopathy is a genetically heterogeneous disease. J Clin Invest. 1990 Sep; 86(3):993-9.
    View in: PubMed
  238. Solomon SD, Geisterfer-Lowrance AA, Vosberg HP, Hiller G, Jarcho JA, Morton CC, McBride WO, Mitchell AL, Bale AE, McKenna WJ, et al. A locus for familial hypertrophic cardiomyopathy is closely linked to the cardiac myosin heavy chain genes, CRI-L436, and CRI-L329 on chromosome 14 at q11-q12. Am J Hum Genet. 1990 Sep; 47(3):389-94.
    View in: PubMed
  239. Jarcho JA, McKenna W, Pare JA, Solomon SD, Holcombe RF, Dickie S, Levi T, Donis-Keller H, Seidman JG, Seidman CE. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med. 1989 Nov 16; 321(20):1372-8.
    View in: PubMed
  240. Fischbein A, Bekesi JG, Solomon S, Borek E, Sharma OK. Modified nucleosides in patients with acquired immune deficiency syndrome (AIDS) and individuals at high risk of AIDS: correlations with lymphadenomegaly and immunological parameters. Cancer Detect Prev Suppl. 1987; 1:589-96.
    View in: PubMed
  241. Suthanthiran M, Williams PS, Solomon SD, Rubin AL, Stenzel KH. Induction of cytolytic activity by anti-T3 monoclonal antibody. Activation of alloimmune memory cells and natural killer cells from normal and immunodeficient individuals. J Clin Invest. 1984 Dec; 74(6):2263-71.
    View in: PubMed
  242. Suthanthiran M, Solomon SD, Williams PS, Rubin AL, Novogrodsky A, Stenzel KH. Hydroxyl radical scavengers inhibit human natural killer cell activity. Nature. 1984 Jan 19-25; 307(5948):276-8.
    View in: PubMed
  243. Solomon S, Hotchkiss E, Saravay SM, Bayer C, Ramsey P, Blum RS. Impairment of memory function by antihypertensive medication. Arch Gen Psychiatry. 1983 Oct; 40(10):1109-12.
    View in: PubMed
  244. Solomon PR, Solomon SD, Schaaf EV, Perry HE. Altered activity in the hippocampus is more detrimental to classical conditioning than removing the structure. Science. 1983 Apr 15; 220(4594):329-31.
    View in: PubMed
  245. Gardner KD, Solomon S, Fitzgerrel WW, Evan AP. Function and structure in the diphenylamine-exposed kidney. J Clin Invest. 1976 Mar; 57(3):796-806.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Solomon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (639) concept(s)
_
Co-Authors
See all (74) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_